Introduction: Obesity and body mass index (BMI) are risk factors for different types of cancer, yet there is no clear association to non-cardia gastric cancer. Bariatric surgery is the most effective treatment for obesity. Incidence of gastric cancer after bariatric surgery remains unclear. The first case report of gastric cancer 4 years following a vertical sleeve gastrectomy was reported in 2014 and up until now, only 11 cases have been reported. Case report: 52-year-old man, who had undergone a sleeve gastrectomy 5 years ago, presented clinical, endoscopic, and histological features, compatible with a gastric body ade-nocarcinoma. He received neoadjuvant chemotherapy of 6 cycles of FLOT, an oncological laparoscopic total gastrectomy with D2 lymph node dissection and adjuvant chemotherapy with 6 cycles of FOLFOX. Biopsy reported a poorly differentiated adenocarcinoma with a 90% of tumor regression, with no signs of ganglion metastases (pT1bN0M0). 6-month follow-up showed no clinical or imaging signs of relapse. Discussion: There is a direct association between higher BMI and gastroesophageal junction cancer, but no clear evidence of this association with non-cardia gastric cancer. The preoperative evaluation with an upper endoscopy before bariatric surgery is not standardized, yet it is possible to recommend it. Bariatric surgery could lower the risk of certain cancers, yet the incidence of gastric cancer after this procedure is not yet defined. Endoscopic follow-up is recommended to all postoperative patients, especially if they become symptomatic.